The presentation videos and slides for speakers’ lectures are made available, provided that they have granted us permission to do so.
Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022
Related Enduring Materials
Enduring Materials
Tuesday, 17 May 2022 -
Catia Marzolini, PharmD, PhD
Oral Antivirals for COVID-19: How to Best Make Use of Their Therapeutic Effects
Oral Antivirals for COVID-19: Drug-Drug Interactions as a Manageable Risk
Case-Based Discussion of Oral Antivirals for COVID-19: Learning from Experience - Part 1
University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom
Case-Based Discussion of Oral Antivirals for COVID-19: Learning from Experience – Part 2
Overview
Image
What's New
The two additional editions of the Course on Clinical Pharmacology of SARS-CoV-2 Antivirals, previously scheduled on 6 September and 1 November, have been postponed indefinitely. Make sure you are signed up for our newsletter to stay updated on developments.
About this Program
The COVID-19 pandemic has had a huge toll in terms of morbidity and mortality worldwide. Immunocompromised patients as well as patients over the age of 60 with comorbidities and underlying conditions are the most at risk of developing severe disease as a result of COVID-19. These patients are also exposed to multiple medications to treat their chronic conditions. Therefore, if they require treatment for COVID-19 with new SARS-CoV-2 antivirals, this can lead to a number of potential complex and serious drug-drug interactions that can result in severe side effects, or reduce the drugs’ therapeutic effect.
The Course on Clinical Pharmacology of SARS-CoV-2 Antivirals gathered healthcare professionals that prescribe oral antivirals for COVID-19 to discuss their therapeutic effects, the management of drug-drug interactions, and the identification of risk factors, as well as leaving ample time for case-based discussions.
Program Directors
General Information
Topics of Interest
The course covers the following topics:
-Oral antivirals for COVID-19 and how to best make use of their therapeutic effects;
-Drug-Drug interactions & risk managements
-Case-base discussions
-Oral antivirals for COVID-19 and how to best make use of their therapeutic effects;
-Drug-Drug interactions & risk managements
-Case-base discussions
Who Should Attend?
Healthcare professionals responsible for prescribing oral antivirals for COVID-19 patients.
Learning objectives
After participating in this activity, participants will be able to:
-Summarize the therapeutic effects of oral antivirals for COVID-19;
-Describe drug-drug interactions of oral antivirals for COVID-19;
-Recognize the challenges associated with the use and the management of oral antivirals for COVID-19.
-Summarize the therapeutic effects of oral antivirals for COVID-19;
-Describe drug-drug interactions of oral antivirals for COVID-19;
-Recognize the challenges associated with the use and the management of oral antivirals for COVID-19.
Practical Information
We trust that the following information will assist you in organizing your participation in the Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022.
Certificate of Attendance
A digital certificate of attendance will be sent to participants that have successfully completed the program and post-meeting survey.
Language
The official language of the webinar is English. Translation will not be provided.
Liability and Insurance
By registering for the webinar, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Support
Support Our Initiative
In order to deliver this program and allow healthcare professionals to attend, we depend on financial support.
We would like to encourage you to show your commitment to knowledge sharing and education on this important topic
By supporting this program, you will help to improve patient care and contribute to the fight against COVID-19.
Your support will be greatly appreciated!
Please contact Ms. Federica Ressa at federica@amededu.com or call +31 30 230 7140.
